Eisai's US perampanel resubmission accepted for review
This article was originally published in Scrip
Executive Summary
The US FDA has formally accepted for review Eisai's resubmission of a new drug application for its novel epilepsy product perampanel, setting the Prescription Drug User Fee Act target date for 22 October.